GET DAILY SIGNALSBionano Genomics (BNGO) and the Path to Its $5 Analyst Target
Key Takeaways
- The central $5 target represents the arithmetic mean of two verified analyst price targets: $4 from Maxim Group and $6 from H.C. Wainwright.
- With the stock near $1.16, reaching $5 would require a roughly 330% advance—a very large move by any standard.
- The two current targets form a wide $4–$6 range, reflecting genuine disagreement about how quickly optical genome mapping (OGM) adoption converts to revenue.
- Supporting factors include growing clinical adoption, reimbursement wins, and rising revenue; the biggest risks are continued losses, dilution, and a going-concern flag from the company's auditor.
- For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages covering the stock's key developments and data.
- You can also explore Trending AI Robots to see AI-driven trading strategies monitoring opportunities across the market.
What the Analysts Are Saying
Bionano Genomics (Nasdaq: BNGO) is a San Diego-based life sciences instrumentation company that sells the Saphyr and Stratys systems for optical genome mapping (OGM), a technique used to detect structural variants in DNA that conventional methods can miss. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Only two current, attributable analyst targets could be verified. Maxim Group's Jason McCarthy reiterated a Buy rating with a $4 target in late May 2026, while H.C. Wainwright's Yi Chen lowered his target to $6 from $7 in April 2026 while keeping a Buy. The arithmetic mean of these two figures is $5.00, which is the central target used here. The range is wide—$4 to $6—which, on a sub-$2 stock, is a meaningful spread of opinion.
Both analysts lean constructive, but their reasoning differs on pace rather than direction: the lower target reflects a more conservative view on how fast OGM utilization and instrument placements translate into durable revenue, while the higher target assigns more credit to reimbursement progress and expanding clinical evidence. Notably, neither target implies a consensus in the traditional sense, since coverage is thin. A third data source, Weiss Ratings, recently issued an upgrade, but it does not publish a price target comparable to the two brokerage figures above.
Current Market Position and Path Toward the Target
The stock closed near $1.16, toward the low end of its 52-week range of roughly $1.00 to $2.23, with a market capitalization around $14 million. Reaching $5 would require an advance of approximately 330%—an extremely large move that would represent a re-rating of the entire company rather than a routine step higher.
The path would almost certainly depend on sustained, accelerating revenue growth and progress toward profitability. The company reported 21% revenue growth and a 53% gross margin in its second quarter of 2026, raised its full-year outlook, and guided to $8.2–$8.6 million in third-quarter revenue. Trailing-twelve-month revenue was about $30 million against a net loss of roughly $32 million, so the business remains firmly unprofitable on an EPS (earnings per share) basis. A move toward $5 would require investors to price in years of future adoption today.
What Could Support a Move Toward the Target
The most credible supports are operational and regulatory. New York State's Department of Health approval of OGM-based lab developed tests (LDTs) and a proposed MolDX local coverage determination for structural-variant testing in blood cancers both point toward reimbursement, a key hurdle for clinical adoption. Peer-reviewed studies from institutions such as MD Anderson Cancer Center continue to show OGM detecting abnormalities that karyotyping and FISH miss. The company also retired its senior secured convertible debentures in May 2026, simplifying the balance sheet.
If utilization among existing customers keeps growing and reimbursement expands, the revenue multiple the market assigns to BNGO could expand—though that is an interpretation, not a forecast.
What Could Prevent the Target From Being Reached
The obstacles are substantial. The company's auditor, BDO LLP, expressed doubt about Bionano's ability to continue as a going concern in the 2025 Form 10-K, citing funding and liquidity risk. The company has repeatedly raised capital, including a registration filing in late 2026 tied to warrant exercises, which can dilute existing shareholders. With a market cap near $14 million and short interest reported at roughly 18% of the float, the stock is vulnerable to sharp swings. Any slowdown in instrument placements, weaker consumable pull-through, or a dilution event could keep the shares anchored well below $5.
Technical Levels and Market Structure
The $1.00 level has acted as a notable psychological and technical floor, marking the lower bound of the 52-week range. The $2.20–$2.25 zone, the prior year's high, stands out as the first major overhead resistance a sustained rally would need to clear. Because the stock trades on very low float and high relative volume, technical levels can shift quickly and should be treated cautiously rather than as reliable support or resistance.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though the two covering firms do not publish identical assumptions, and neither horizon is guaranteed. The most immediate catalyst is the company's third-quarter 2026 report, scheduled for November 10, 2026. Investors should watch revenue and guidance, gross margin, cash runway and any financing announcements, reimbursement decisions, and any change to the going-concern language in subsequent filings.
Using Tickeron’s AI Tools in Practice
For traders tracking names like BNGO, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to keep pace with changing conditions. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from evolving market behavior, technical patterns, and AI-driven analysis. Traders can use these signals to surface new opportunities, monitor existing positions, and spot shifting trends more efficiently than scanning charts manually. I find this approach helpful for staying on top of developments without having to review every chart by hand.
Final Assessment
Whether Bionano Genomics can reach $5 ultimately depends on execution that has not yet been proven. The target—the mean of a $4 Maxim Group view and a $6 H.C. Wainwright view—implies roughly 330% upside from current levels, an extremely demanding move for a micro-cap company that is still losing money and carries a going-concern warning. The bullish case rests on real momentum: rising revenue, gross-margin improvement, reimbursement approvals, and an expanding body of clinical evidence for OGM. The bearish case is equally concrete: thin cash, recurring dilution, and a share structure that leaves little margin for error. The two analysts disagree meaningfully on pace, and with only two targets available, no firm "analyst consensus" should be inferred. What to watch next is straightforward: the quarterly report, cash runway, and whether reimbursement and utilization growth can outpace the company's need for capital.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BNGO's Indicator enters downward trend
The Aroon Indicator for BNGO entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 321 similar instances where the Aroon Indicator formed such a pattern. In 290 of the 321 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
BNGO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNGO crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BNGO's RSI Indicator exited the oversold zone, 32 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 66 cases where BNGO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BNGO as a result. In 68 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for BNGO just turned positive on November 09, 2026. Looking at past instances where BNGO's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
Following a +5.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in 165 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.429) is normal, around the industry mean (4.964). P/E Ratio (-0.382) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technologies for analysis of large biological molecules
Industry PharmaceuticalsOther
Advertisement